ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Investment Case for a Comprehensive Package of Interventions Against Hepatitis B in China: Applied Modeling to Help National Strategy Planning.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Chronic Hepatitis B in the Asia-Pacific Region: Results of the 2023 Global Burden of Disease Study.Journal of clinical and translational hepatology · 2026Article
- Spatio-temporal clustering characteristics of hepatitis B in China: an 18-year study.Scientific reports · 2026Article
- Medication adherence and associated factors in patients with chronic hepatitis B in Zhejiang Province, Eastern China.BMC public health · 2026Article
- Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study.Infectious Disease Modelling · 2026Article
- Curative care expenditure across different comorbidity states of chronic hepatitis B: a prevalence study in Sichuan Province, China.BMJ open · 2025Article
- Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China.Journal of clinical and translational hepatology · 2025Review
- Modeling hepatitis B-related deaths in China to achieve the WHO's impact target.Infectious Disease Modelling · 2025Article
- [Recent advances in epidemiology, prevention and treatment of hepatitis B in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Changes in the prevalence of hepatitis B virus and its related factors in Inner Mongolia between 2006 and 2020.Frontiers in public health · 2025Article
- Effect of Health Literacy on Antiviral Treatment of Hepatitis B: Instrumental Variable Analysis.JMIR public health and surveillance · 2024Article
- New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020.The Lancet regional health. Western Pacific · 2024Article
- Comprehensive approach to controlling chronic hepatitis B in China.Clinical and molecular hepatology · 2024Review
- Comparison of the effectiveness four years after Homo/Hetero prime-boost with 10 μg HP and 20 μg CHO recombinant hepatitis B vaccine at 1 and 6 months in maternal HBsAg-negative children.Frontiers in immunology · 2024Article
- Blueprint to hepatitis B elimination in China: A modelling analysis of clinical strategies.JHEP reports : innovation in hepatology · 2023Article
- Impact and Cost-Effectiveness of Biomedical Interventions on Adult Hepatitis B Elimination in China: A Mathematical Modelling Study.Journal of epidemiology and global health · 2023Article
- Changing incidence of hepatitis B and persistent infection risk in adults: a population-based follow-up study from 2011 in China.BMC public health · 2023Article
- Exploring the Public Health and Social Implications of Future Curative Hepatitis B Interventions.Viruses · 2022Article
- Costs and health impact of delayed implementation of a national hepatitis B treatment program in China.Journal of global health · 2022Article
- Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.Journal of clinical and translational hepatology · 2022Article
- Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.The Lancet. Global health · 2022Article
Corrections and comments
- Commented on by
Authors and funding
24 authors at 11 institutions in 5 countries.
Funding
Abstract
backgroundIn 2016, the first global viral hepatitis elimination targets were endorsed. An estimated one-third of the world's population of individuals with chronic hepatitis B virus (HBV) infection live in China and liver cancer is the sixth leading cause of mortality, but coverage of first-line antiviral treatment was low. In 2015, China was one of the first countries to initiate a consultative process for a renewed approach to viral hepatitis. We present the investment case for the scale-up of a comprehensive package of HBV interventions.
methodsA dynamic simulation model of HBV was developed and used to simulate the Chinese HBV epidemic. We evaluated the impact, costs, and return on investment of a comprehensive package of prevention and treatment interventions from a societal perspective, incorporating costs of management of end-stage liver disease and lost productivity costs.
resultsDespite the successes of historical vaccination scale-up since 1992, there will be a projected 60 million people still living with HBV in 2030 and 10 million HBV-related deaths, including 5.7 million HBV-related cancer deaths between 2015 and 2030. This could be reduced by 2.1 million by highly active case-finding and optimal antiviral treatment regimens. The package of interventions is likely to have a positive return on investment to society of US$1.57 per US dollar invested.
conclusionsIncreases in HBV-related deaths for the next few decades pose a major public health threat in China. Active case-finding and access to optimal antiviral treatment are required to mitigate this risk. This investment case approach provides a real-world example of how applied modeling can support national dialog and inform policy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.